Cytokinetics sues BMS/MyoKardia over patent on MYQORZO (aficamten)

CYTOKINETICS INC

Filed complaint in U.S. District Court for Delaware against Bristol-Myers Squibb and MyoKardia over U.S. Patent No. 12,616,697.
Seeks declaratory judgment that Cytokinetics does not infringe and that the '697 patent claims are invalid.
Requests injunction barring defendants from threatening infringement litigation against MYQORZO (aficamten) users, customers, and distributors.
Also seeks costs, attorneys' fees, and a jury trial; company says it will vigorously assert its rights.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.